Briggs Morrison - 09 Jun 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Issuer symbol
SNDX
Transactions as of
09 Jun 2023
Net transactions value
-$714,634
Form type
4
Filing time
09 Jun 2023, 17:32:28 UTC
Previous filing
12 Jun 2023
Next filing
20 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $156,833 +24,582 +138% $6.38 42,418 09 Jun 2023 Direct
transaction SNDX Common Stock Options Exercise $247,954 +28,273 +67% $8.77 70,691 09 Jun 2023 Direct
transaction SNDX Common Stock Sale $520,625 -24,582 -35% $21.18 46,109 09 Jun 2023 Direct F1, F2
transaction SNDX Common Stock Sale $598,797 -28,273 -61% $21.18 17,836 09 Jun 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -28,273 -100% $0.000000* 0 09 Jun 2023 Common Stock 28,273 $8.77 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24,582 -100% $0.000000* 0 09 Jun 2023 Common Stock 24,582 $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Following the sales reported in this Form 4, the Reporting Person has a total of 643,144 options to purchase shares of common stock that are vested and immediately exercisable and a total of 269,583 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $20.94 to $21.58.
F3 This option is fully vested.